As of 2026, the clinical and commercial landscape for inflammatory spinal disorders has reached a record valuation, with the Axial Spondyloarthritis Market Size estimated to have crossed the USD 7.09 billion mark globally. This robust valuation is primarily underpinned by the widespread adoption of high-value biologic therapies and the emergence of non-radiographic axial spondyloarthritis...